Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
about
Endothelin receptor antagonists for pulmonary arterial hypertensionEndothelin receptor antagonists for pulmonary arterial hypertensionProstacyclin for pulmonary hypertension in adultsComparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-AnalysisTreprostinil for the treatment of pulmonary arterial hypertensionIn vitro microvessels for the study of angiogenesis and thrombosis.Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysisClinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review.Experiences with treprostinil in the treatment of pulmonary arterial hypertension.Cardiac manifestations in systemic sclerosis.Integrated care and optimal management of pulmonary arterial hypertensionProstacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes.Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.Prostanoid therapies in the management of pulmonary arterial hypertension.Emerging drugs in the management of hypertension.Treprostinil for pulmonary hypertension.Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disordersTransition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single centerComparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertensionPharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years.Pulmonary arterial hypertension: classification, diagnosis and contemporary management.Intra-abdominal bleeding during treprostinil infusion in a patient with pulmonary arterial hypertension.Current therapies for pulmonary arterial hypertension.Updated evidence-based treatment algorithm in pulmonary arterial hypertension.Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trialsChildren with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertensionPharmacokinetic evaluation of continuous intravenous epoprostenol.Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.Treatment of pulmonary arterial hypertension in connective tissue disease.Inhaled treprostinil for the treatment of pulmonary arterial hypertension.Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.Optimal use of treprostinil in pulmonary arterial hypertension: a guide to the correct use of different formulations.Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.Impact on Survival of Warfarin in Patients with Pulmonary Arterial Hypertension Receiving Subcutaneous Treprostinil.Diagnostic and therapeutic algorithm for pulmonary arterial hypertension.
P2860
Q24200714-41F7FDB0-705A-4C9C-B080-318BC0FC401BQ24240009-872F98CD-2096-40AA-ADF2-8292916BD328Q24246933-E60A46FC-8662-438E-899C-3BC098016823Q26772960-AEC7A1A7-A7F4-4402-8610-5E83F466816EQ28281899-46C9FD1F-A1F8-4E3E-99F5-25A84071A9E6Q30519206-2F467704-37D9-46E9-865E-63E9F3AC4B97Q33673947-503180C6-C721-411C-A163-B06CF4262924Q33715766-928F4156-9BB8-492D-BA31-80AEF299238AQ33816571-8ACD0D8F-B369-436B-9FE7-02517A301A89Q33982476-D84B9D8C-0115-4337-99BE-459C721C17F8Q34251904-25B3DA3F-2C89-4D35-A852-6418CC2EC92BQ34417785-90BA8B58-4286-4673-8F85-D7A91C6852D3Q34790785-8EA3FDD8-C031-4C4D-866A-3A441986BD09Q34985436-905318F1-C44F-487C-ABDC-C17EAA283080Q35284318-84FDC824-9C12-4752-BC53-3B1968D9C8D5Q35602652-627D30B7-E476-411A-BF74-B81D8DB62E7FQ35777345-C8A4AD80-9B0E-4986-90CE-CFA711DF5F5CQ35792872-C0FB8EA2-4B8D-46E9-B9D2-073D876593E6Q35829890-3A08B2F1-C6FD-40A7-B38D-47098EAC720EQ35987352-153FAF19-1CB1-4BE8-8FCF-79CCF3FA2F7AQ36016519-AC7ACD1A-7F0B-448D-B31D-D2ACA1AE0C8CQ36129391-8404B84C-FE41-4D21-9227-23A2391D2406Q36325779-8B0E76A8-C7A6-4750-A253-FE46C1449236Q36408727-AAB0CE6B-FCBF-478D-BE77-05D22441C786Q36651071-A43F4622-D453-4E67-A799-094055DDE081Q36704611-6B0E4E31-5B7E-4C73-B8B0-5AA3259141B3Q36834630-ACFD17B3-5F60-45DD-87EB-A6C72D3E7AF6Q36939543-E61C541C-9C7B-480F-85FC-D6893577A04AQ37069668-C3218A89-F19F-4D14-9479-28C3235E114CQ37139801-9E15A1F1-EC20-497F-82D5-467449B136A7Q37555352-AF1B99EA-4E5D-4E02-8C92-66C915D61C37Q37809538-121EE72C-716F-4EA8-9890-46491AB76C5DQ37879213-52305329-DEDF-4923-B37D-F48ABEBA52D8Q38012530-E90C97C9-6D63-4D4B-8DD0-9712088DB9DEQ38025723-9123ABCE-549C-413A-A4D1-6C78B939F834Q38027095-65B591A6-D6E8-4D51-A285-F593B649F803Q38066529-5C8D9A70-2580-48CD-8CB3-CA167C5FBBBFQ38175430-705649F6-AC78-4433-A269-914B2C0779C9Q38712639-8B9CEE4D-5EF9-4C58-A744-F5660935F39BQ38782951-CB1ECE4B-1214-4A1B-B433-3EC613B0922A
P2860
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Efficacy and safety of trepros ...... rimary pulmonary hypertension.
@en
Efficacy and safety of trepros ...... rimary pulmonary hypertension.
@nl
type
label
Efficacy and safety of trepros ...... rimary pulmonary hypertension.
@en
Efficacy and safety of trepros ...... rimary pulmonary hypertension.
@nl
prefLabel
Efficacy and safety of trepros ...... rimary pulmonary hypertension.
@en
Efficacy and safety of trepros ...... rimary pulmonary hypertension.
@nl
P2093
P1476
Efficacy and safety of trepros ...... rimary pulmonary hypertension.
@en
P2093
Adaani Frost
Carl Arneson
David B Badesch
Ivan M Robbins
Jeff Sigman
Lewis J Rubin
Michael D McGoon
Robert C Bourge
Robert Roscigno
Robyn J Barst
P304
P356
10.1097/00005344-200302000-00019
P577
2003-02-01T00:00:00Z